Home » Sun Pharma Gets U.S. 180-Day Exclusivity
Sun Pharma Gets U.S. 180-Day Exclusivity
Sun Pharma has become the third Indian pharmaceutical company after Dr. Reddy’s and Ranbaxy to gain 180-day exclusive marketing rights to launch a generic drug in the U.S. market, following the U.S. approval for launching a heartburn and anti-ulcer drug.
Business Standard
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May